Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN3500 and Dupilumab in Allergic Asthma
NCT03112577Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of itepekimab in allergic asthma (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Change in sputum inflammatory markers at 4 weeks. Started Jun 2017; status: completed.
02
Drugs
itepekimab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT03112577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03112577.